UM  > 中華醫藥研究院
The alarmin HMGN1 contributes to antitumor immunity and is a potent immunoadjuvant
Wei F.1,2; Yang D.1,3,4; Tewary P.1,4; Li Y.1; Li S.1; Chen X.1,4; Howard O.M.Z.1; Bustin M.5; Oppenheim J.J.1
2014-11-01
Source PublicationCancer Research
ISSN15387445 00085472
Volume74Issue:21Pages:5989-5998
Abstract

Alarmins are endogenous mediators that are elicited rapidly in response to danger signals, enhancing innate and adaptive immune responses by promoting the recruitment and maturation of antigen-presenting cells (APC). The nucleosome-binding protein HMGN1 is a potent alarmin that binds TLR4 and induces antigen-specific Th1 immune responses, but its contributions to antitumor immunity have not been explored. We found that ovalbumin (OVA)-expressing EG7 mouse thymoma cells grew much faster in Hmgn1-deficient mice than littermate-matched controls. Tumor-bearing Hmgn1 mice generated fewer OVA-specific CD8 cells in the spleen than EG7-bearing Hmgn1 mice, suggesting that HMGN1 supported T cell-mediated antitumor immunity. In addition, EG7 tumors expressing HMGN1 grew more slowly than control EG7 tumors, suggesting greater resistance to HMGN1-expressing tumors. This resistance relied on T cell-mediated immunity because it was abolished by in vivo depletion of CD4 and CD8 T cells. Moreover, mice vaccinated with a DNA vector expressing an HMGN1-gp100 fusion protein manifested gp100-specific, Th1-polarized immune responses, acquiring resistance to challenge with mouse B16F1 melanoma. Overall, our findings show that HMGN1 contributes to antitumor immunity and it may offer an effective adjuvant to heighten responses to cancer vaccines.

DOI10.1158/0008-5472.CAN-13-2042
URLView the original
Indexed BySCI
WOS Research AreaOncology
WOS SubjectOncology
WOS IDWOS:000344756800007
Fulltext Access
Citation statistics
Cited Times [WOS]:28   [WOS Record]     [Related Records in WOS]
Document TypeJournal article
CollectionInstitute of Chinese Medical Sciences
Affiliation1.1 Laboratory of Molecular Immunoregulation, Cancer and Inflammation Program, Center for Cancer Research, Frederick National Laboratory for Cancer Research (FNLCR), Frederick, Maryland.
2.Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
3.Research Center of Basic Medical Sciences, Tianjin Medical University, Tianjin, China.
4.Basic Research Program, Leidos Biomedical Research, Inc., Frederick National Laboratory, Frederick, Maryland
5.Laboratory of Metabolism, National Cancer Institute, NIH, Bethesda, Maryland.
Recommended Citation
GB/T 7714
Wei F.,Yang D.,Tewary P.,et al. The alarmin HMGN1 contributes to antitumor immunity and is a potent immunoadjuvant[J]. Cancer Research,2014,74(21):5989-5998.
APA Wei F..,Yang D..,Tewary P..,Li Y..,Li S..,...&Oppenheim J.J..(2014).The alarmin HMGN1 contributes to antitumor immunity and is a potent immunoadjuvant.Cancer Research,74(21),5989-5998.
MLA Wei F.,et al."The alarmin HMGN1 contributes to antitumor immunity and is a potent immunoadjuvant".Cancer Research 74.21(2014):5989-5998.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Google Scholar
Similar articles in Google Scholar
[Wei F.]'s Articles
[Yang D.]'s Articles
[Tewary P.]'s Articles
Baidu academic
Similar articles in Baidu academic
[Wei F.]'s Articles
[Yang D.]'s Articles
[Tewary P.]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[Wei F.]'s Articles
[Yang D.]'s Articles
[Tewary P.]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.